When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?
作者信息
Adams Jared R, Angelotta Cara, Bennett Charles L
出版信息
J Clin Oncol. 2006 Jul 1;24(19):2975-7. doi: 10.1200/JCO.2006.05.6812. Epub 2006 May 8.
PMID:16682722
Abstract
摘要
Zotero 插件